Abstract
Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review identifies a series of promising drugs that hopefully will be available to complete our current armory.
Keywords: Nicotine replacement therapy, bupropion, varenicline, psychiatric, clonidine, nortriptyline, lozenge, cessation, acetylcholine, pulsatile, alkaloids, galenic, libitum, dyspepsia, tremor, insomnia
Current Pharmaceutical Design
Title: Pharmacotherapy for Smoking Cessation: Present and Future
Volume: 17 Issue: 14
Author(s): Henri-Jean Aubin, Laurent Karila and Michel Reynaud
Affiliation:
Keywords: Nicotine replacement therapy, bupropion, varenicline, psychiatric, clonidine, nortriptyline, lozenge, cessation, acetylcholine, pulsatile, alkaloids, galenic, libitum, dyspepsia, tremor, insomnia
Abstract: Tobacco dependence is a chronic disease that often requires repeated interventions and multiple attempts to quit. To date, three medications are FDA-approved for smoking cessation: nicotine replacement therapy, sustained-release bupropion, and varenicline. These treatments are effective across a broad range of populations, and are recommended for all smokers, including those with psychiatric or addictive comorbidity. Less is known however concerning the benefit-risk profile of these medications in pregnant women and adolescents. With these limitations in mind, clinicians should encourage and offer counseling and a prescription of pharmacotherapy to every patient willing to make a quit attempt. Despite the relative efficacy of first-line medications, many smokers relapse after one given quit attempt, and alternative pharmacotherapies are needed. Clonidine and nortriptyline have been proposed as second-line medications. In addition, this review identifies a series of promising drugs that hopefully will be available to complete our current armory.
Export Options
About this article
Cite this article as:
Aubin Henri-Jean, Karila Laurent and Reynaud Michel, Pharmacotherapy for Smoking Cessation: Present and Future, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150837
DOI https://dx.doi.org/10.2174/138161211796150837 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Hymenoptera Venom Proteins and Peptides for Diagnosis and Treatment of Venom Allergic Patients
Inflammation & Allergy - Drug Targets (Discontinued) C1 Inhibitor Administration Reduces Local Inflammation and Capillary Leakage, Without Affecting Long-term Wound Healing Parameters, in a Pig Burn Wound Model
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metal Allergens of Growing Significance: Epidemiology, Immunotoxicology, Strategies for Testing and Prevention
Inflammation & Allergy - Drug Targets (Discontinued) The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Current Molecular Medicine Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Current Options for the Pharmacotherapy of Obesity
Current Pharmaceutical Design Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued) Novel Drugs for Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Cytokine Profile in Patients Infected with Anisakis simplex in Endemic Areas: Dietary Intervention with Polyphenols: A Working Hypothesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot topic: Recent Progress in Cancer Therapeutics (Guest Editor: Kurt S. Zaenker)]
Current Molecular Medicine Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry Designing Peptidomimetics
Current Topics in Medicinal Chemistry